Robert J. Warden

Array ( [id] => 18575461 [patent_doc_number] => 11731974 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists [patent_app_type] => utility [patent_app_number] => 17/066086 [patent_app_country] => US [patent_app_date] => 2020-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 22502 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17066086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18179453 [patent_doc_number] => 20230040182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS [patent_app_type] => utility [patent_app_number] => 17/766837 [patent_app_country] => US [patent_app_date] => 2020-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 397 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581427 [patent_doc_number] => 20210015829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => CYCLIC TREX1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/064320 [patent_app_country] => US [patent_app_date] => 2020-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 625 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17064320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960002 [patent_doc_number] => 20220340582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => CANNABINOID DERIVATIVES [patent_app_type] => utility [patent_app_number] => 17/765853 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126101 [patent_doc_number] => 20210300869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => MODULATORS OF ROR-GAMMA [patent_app_type] => utility [patent_app_number] => 17/032428 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17032428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929739 [patent_doc_number] => 20220324864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => Pyrazolopyridine Compounds as Selective BTK Kinase Inhibitors [patent_app_type] => utility [patent_app_number] => 17/763732 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854881 [patent_doc_number] => 20210155626 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => MODULATION OF IRE1 [patent_app_type] => utility [patent_app_number] => 17/031132 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17031132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18150663 [patent_doc_number] => 20230024521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => JAK INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/762625 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18140889 [patent_doc_number] => 20230014730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => PHOSPHODIESTERASE INHIBITORS AND USE [patent_app_type] => utility [patent_app_number] => 17/641633 [patent_app_country] => US [patent_app_date] => 2020-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613604 [patent_doc_number] => 20210032257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7 [patent_app_type] => utility [patent_app_number] => 17/028334 [patent_app_country] => US [patent_app_date] => 2020-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17028334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18294597 [patent_doc_number] => 20230104283 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => JNK INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/754333 [patent_app_country] => US [patent_app_date] => 2020-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17754333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18057939 [patent_doc_number] => 20220389025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/761252 [patent_app_country] => US [patent_app_date] => 2020-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17039 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711851 [patent_doc_number] => 20210078998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/020122 [patent_app_country] => US [patent_app_date] => 2020-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 116684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17020122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17959984 [patent_doc_number] => 20220340564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => ANTIBACTERIAL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/639963 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49788 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17639963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036159 [patent_doc_number] => 20220380374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 17/642142 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16557138 [patent_doc_number] => 20210002286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => IMIDAZOTETRAZINE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/017475 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18004921 [patent_doc_number] => 20220363687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => TRICYCLIC JANUS KINASE (JAK) INHIBITORS AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 17/640357 [patent_app_country] => US [patent_app_date] => 2020-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621438 [patent_doc_number] => 20210040091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS [patent_app_type] => utility [patent_app_number] => 17/009450 [patent_app_country] => US [patent_app_date] => 2020-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17009450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720047 [patent_doc_number] => 20210087194 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => Chemical Process for Preparing Imidazopyrrolidinone Derivatives and Intermediates Thereof [patent_app_type] => utility [patent_app_number] => 17/009215 [patent_app_country] => US [patent_app_date] => 2020-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7509 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17009215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17800114 [patent_doc_number] => 11414394 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => Process for producing a hydrate of a hydrochloride salt of 2,2'-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid [patent_app_type] => utility [patent_app_number] => 17/005597 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51048 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17005597 [rel_patent_id] =>[rel_patent_doc_number] =>)